Dougherty's Pharmacy

CLOSEOUT LETTER Dougherty's Pharmacy MARCS-CMS 500635 — May 14, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: 2017-DAL-WL-22 Product: Drugs Recipient: Recipient Name Stewart I. Edington Recipient Title President/CEO Dougherty's Pharmacy 5924 Royal Lane Suite 250 Dallas , TX 75230 United States Issuing Office: Office of Pharmaceutical Quality Operations Division II United States Mr. Edington: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL # 2017-DAL-WL-22), dated May 12, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. If you have any question, please do not hesitate to contact me at John.Diehl@fda.hhs.gov . Sincerely, /S/ CDR John W. Diehl, M.S. Director, Compliance Branch Office of Pharmaceutical Quality Operations, Division II Content current as of: 05/22/2020 Regulated Product(s) Drugs